Infection Control News

The FDA on Tuesday approved letermovir for the prevention of cytomegalovirus disease in high-risk adult kidney transplant recipients, Merck announced.

Transplant medicine and the field of transplant infectious diseases have faced numerous disruptions and challenges during the COVID-19 pandemic, according to experts.

KANSAS CITY, Missouri — In this interview from the Annual Dialysis Conference, Paige Wheatley, PhD, microbiologist at Light Line Medical, discussed the design and pre-clinical findings of the company’s disinfectant system.

The National Kidney Foundation Innovation Fund announced it invested in Revalo to continue developing PeritoneX technology, according to a press release.

The AMA, American Society of Nephrology and CDC announced the launch of new CME modules designed to improve infection control in outpatient dialysis settings, according to the press release.

Adults on dialysis for end-stage kidney disease are 100 times more likely to have a Staphylococcus aureus bloodstream infection than those not on dialysis, according to a new report, which uncovered disparities in the rates of infection.

Letermovir effectively prevented cytomegalovirus disease among kidney transplant patients with fewer side effects than valganciclovir, according to a study presented at IDWeek.

FORT WORTH, Texas— In this video from the American Nephrology Nurses Association Annual Symposium, Peggy Bushey, BSN, RN, CDN, talks about a new technique to reduce access-related blood stream infections.

During the first few waves of COVID-19, kidney transplant recipients in Norway engaged in less social interaction than the general population and strongly adhered to government advice, according to data published in Kidney Medicine.

Although patients on dialysis show a low immunological response to COVID-19 vaccines, they benefit from the general population getting vaccinated, according to data published in the Clinical Journal of the American Society of Nephrology.